Main Outcomes and Measures Disease-free survival. Targeted biomarker analysis, including targeted gene expression ( BUB1B and PINK1), targeted methylation ( PAX5, GSTP1, PYCARD, and PAX6), and targeted next-generation sequencing, was performed on the training and validation cohorts. Data were analyzed from March 2016 to March 2018.Įxposures Meta-analysis of pan-genomic studies (transcriptome, methylome, chromosome alteration, and mutational profiles) was performed on the training cohort. Objective To compare the molecular classification for prognostic assessment of ACC with other known prognostic factors.ĭesign, Setting, and Participants In this retrospective biomarker analysis, ACC tumor samples from 368 patients who had undergone surgical tumor removal were collected from March 1, 2005, to Septem(144 in the training cohort and 224 in the validation cohort) at 21 referral centers with a median follow-up of 35 months (interquartile range, 18-74 months). Pan-genomic studies have identified distinct molecular groups closely associated with outcome. Adjuvant therapy after surgery is recommended for most patients. Importance The risk stratification of adrenocortical carcinoma (ACC) based on tumor proliferation index and stage is limited. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.Molecular classifiers and overall survival in the validation cohort Pan-genomic classification and overall survival in stage IV patients of the training cohortĮFigure 6. Harrell’s C-Indexes for disease-free survival in R0 stage I-III patients of the training cohortĮFigure 5. Patients’ inclusion for survival models in training (A) and validation (B) cohortsĮFigure 4. Targeted molecular classification of ACC (validation cohort)ĮFigure 3. Pan-genomic classification of ACC (training cohort)ĮFigure 2. Univariate analysis of overall survival in stage IV patients of the validation cohortĮFigure 1. Univariate analysis of disease-free survival in the validation cohortĮTable 10. Univariate analysis of overall survival in stage IV patients of the training cohortĮTable 9. Uni- and multivariable analyses of disease-free survival in the training cohortĮTable 8. Association between pan-genomic classes and standard prognostic variablesĮTable 7. Correlation between pan-genomic classification and standard prognostic variablesĮTable 6.
Prognostic value of recurrently altered genes in ACC (training cohort)ĮTable 5. Clinical and molecular data of the validation cohortĮTable 3. Clinical and molecular data of the training cohortĮTable 2. Patients, Pan-genomic Molecular Measures, Targeted Molecular Profiling, and Source CodesĮTable 1.
0 kommentar(er)
